Long QT syndrome is a leading cause of sudden death in young persons, with a prevalence exceeding 1 in 2000. It is characterized by prolongation of the QT interval, aberrant T-wave morphologic ...

Lupin Limited ((IN:LUPIN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Congenital Long QT Syndrome (LQTS) is one of the main causes of sudden cardiac death (SCD) in the pediatric age group, with a prevalence of approximately one case for every 2,000 newborns. The most ...

A recent groundbreaking trial conducted in London United Kingdom revealed that lamotrigine is as effective as mexiletine and can be used as an alternative drug for non-dystrophic myotonias. The trial ...

The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which ...

Researchers found that the mean interactive voice response stiffness score after treatment with mexiletine was 2.54 vs 2.77 with lamotrigine. HealthDay News — Improvements in nondystrophic myotonias ...

WEDNESDAY, Oct. 9, 2024 (HealthDay News) -- Improvements in nondystrophic myotonias symptoms are similar for lamotrigine and mexiletine, according to a study published in the October issue of The ...

A trial at UCL found mexiletine and lamotrigine equally effective in reducing muscle stiffness in non-dystrophic myotonia patients, positioning lamotrigine as a globally accessible alternative. A UCL ...

Lamotrigine, a drug commonly used to treat epilepsy and certain mood disorders, has been shown to be an excellent treatment option for a rare genetic neuromuscular disease known as non-dystrophic ...

The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which ...